Filing Details

Accession Number:
0001193805-25-000195
Form Type:
13G Filing
Publication Date:
2025-02-13 19:00:00
Filed By:
Schonfeld Strategic Advisors
Company:
Reviva Pharmaceuticals Holdings Inc.
Filing Date:
2025-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Schonfeld Strategic Advisors LLC 0 1,314,915 2.82%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The percentage of the issuer's common stock beneficially owned by the reporting person reflects 46,579,199 shares of common stock outstanding, as set forth in (and after giving effect to the offering contemplated by) the prospectus supplement, dated December 16, 2024, filed by the issuer with the Securities and Exchange Commission on December 18, 2024.


SCHEDULE 13G


 
Schonfeld Strategic Advisors LLC
 
Signature:/s/ Mark H. Peckman
Name/Title:Mark H. Peckman/General Counsel and Chief Compliance Officer
Date:02/14/2025